Gil Roth09.20.11
Catalent Pharma Solutions and Toyobo Biologics, Inc. (TBI) have entered into a partnership agreement to co-promote Catalent’s proprietary GPEx technology in the Japanese market. TBI is a biologics supplier and contract provider of large scale clinical and commercial bioreactors in Japan.
GPEx technology is used for mammalian cell line development. It creates stable, high expression cell lines "that will speed biologics drug development to clinic in one-third the time of traditional approaches," according to a Catalent statement. GPEx uses a retrovector technology to ensures stable transduction of targeted cells, approaching 100% efficiency.
“Toyobo's established business reputation in the Japanese market and its biomanufacturing capability makes the partnership a natural synergy to co-promote Catalent’s GPEX technology,” said Kent Payne, vice president and general manager of Catalent’s Development Services business. “Together, Catalent and Toyobo can now offer an advanced cell line development solution for customers in the Japanese market, from gene expression through commercialization of product.”
TBI owns and operates a GMP manufacturing plant with bioreactors ranging from 100L up to 4,000L located in Shiga, Japan. “We are confident TBI’s strong position in the Japanese market, combined with access to Catalent’s proprietary GPEx technology, will create new opportunities to enhance our ability to serve our customers in the region,” stated Yukihiro Sogabe, president, TBI. “We look forward to capitalizing on these opportunities and leveraging future successes together.”
GPEx technology is used for mammalian cell line development. It creates stable, high expression cell lines "that will speed biologics drug development to clinic in one-third the time of traditional approaches," according to a Catalent statement. GPEx uses a retrovector technology to ensures stable transduction of targeted cells, approaching 100% efficiency.
“Toyobo's established business reputation in the Japanese market and its biomanufacturing capability makes the partnership a natural synergy to co-promote Catalent’s GPEX technology,” said Kent Payne, vice president and general manager of Catalent’s Development Services business. “Together, Catalent and Toyobo can now offer an advanced cell line development solution for customers in the Japanese market, from gene expression through commercialization of product.”
TBI owns and operates a GMP manufacturing plant with bioreactors ranging from 100L up to 4,000L located in Shiga, Japan. “We are confident TBI’s strong position in the Japanese market, combined with access to Catalent’s proprietary GPEx technology, will create new opportunities to enhance our ability to serve our customers in the region,” stated Yukihiro Sogabe, president, TBI. “We look forward to capitalizing on these opportunities and leveraging future successes together.”